Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Chronic Heart Failure

  Free Subscription


3 Am J Cardiol
1 Circ Heart Fail
2 Circ Res
5 Circulation
3 Eur Heart J
42 Eur J Heart Fail
1 Heart
1 Int J Cardiol
2 J Mol Cell Cardiol
1 PLoS One

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    Am J Cardiol

  1. AFZAL A, van Zyl J, Nisar T, Kluger AY, et al
    Trends in Hospital Admissions for Systolic and Diastolic Heart Failure in the United States Between 2004 and 2017.
    Am J Cardiol. 2022 Mar 29. pii: S0002-9149(22)00116.
    PubMed         Abstract available

  2. SIONTIS GC, Bhatt DL, Patel CJ
    Secular Trends in Prevalence of Heart Failure Diagnosis over 20 Years (from the US NHANES).
    Am J Cardiol. 2022 Mar 28. pii: S0002-9149(22)00193.

  3. HAN S, Wang C, Tong F, Li Y, et al
    Value of the Neutrophils/Prealbumin Ratio and Its Combination With the GWTG-HF Score in Predicting In-Hospital Mortality in Patients With Heart Failure.
    Am J Cardiol. 2022 Mar 24. pii: S0002-9149(22)00175.
    PubMed         Abstract available

    Circ Heart Fail

  4. VERMA AK, Olagoke O, Moreno JD, Rezaee N, et al
    SARS-CoV-2-Associated Myocarditis: A Case of Direct Myocardial Injury.
    Circ Heart Fail. 2022;15:e008273.

    Circ Res

  5. Correction to: The Cancer Therapy-Related Clonal Hematopoiesis Driver Gene Ppm1d Promotes Inflammation and Non-Ischemic Heart Failure in Mice.
    Circ Res. 2022;130:e23.

  6. MESUBI OO, Anderson ME
    Heart Failure and Atrial Fibrillation-Chicken or Egg?
    Circ Res. 2022;130:1011-1013.


  7. HEGYI B, Mira Hernandez J, Shen EY, Habibi NR, et al
    Empagliflozin Reverses Late Na(+) Current Enhancement and Cardiomyocyte Proarrhythmia in a Translational Murine Model of Heart Failure With Preserved Ejection Fraction.
    Circulation. 2022;145:1029-1031.

  8. BORLAUG BA, Blair J, Bergmann MW, Bugger H, et al
    Latent Pulmonary Vascular Disease May Alter the Response to Therapeutic Atrial Shunt Device in Heart Failure.
    Circulation. 2022 Mar 31. doi: 10.1161/CIRCULATIONAHA.122.059486.
    PubMed         Abstract available

  9. HEIDENREICH PA, Bozkurt B, Aguilar D, Allen LA, et al
    2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.
    Circulation. 2022 Apr 1:101161CIR0000000000001063.
    PubMed         Abstract available

  10. HEIDENREICH PA, Bozkurt B, Aguilar D, Allen LA, et al
    2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.
    Circulation. 2022 Apr 1:101161CIR0000000000001062.
    PubMed         Abstract available

  11. MORRIS AA, Butler J
    The Updated Heart Failure Guidelines: Time for a Refresh.
    Circulation. 2022 Apr 1. doi: 10.1161/CIRCULATIONAHA.122.059104.

    Eur Heart J

  12. OKA S, Endo H, Takagi K, Yamagata K, et al
    Mechanical coronary artery stenosis induced by active fixation left ventricular lead: a case of acute complication after cardiac resynchronization therapy device implantation.
    Eur Heart J. 2022;43:1271.

  13. RUILOPE LM, Ruiz-Hurtado G, Miranda B, Ortiz A, et al
    Use of chronic kidney disease blind spot to prevent cardiorenal outcomes.
    Eur Heart J. 2022;43:257-260.

  14. DMITRIEVA NI, Liu D, Wu CO, Boehm M, et al
    Middle age serum sodium levels in the upper part of normal range and risk of heart failure.
    Eur Heart J. 2022 Mar 29. pii: 6553797. doi: 10.1093.
    PubMed         Abstract available

    Eur J Heart Fail

  15. WITTE KK, Kaye DM, Lipiecki J, Siminiak T, et al
    Treating symptoms and reversing remodelling: clinical and echocardiographic 1-year outcomes with percutaneous mitral annuloplasty for mild to moderate secondary mitral regurgitation.
    Eur J Heart Fail. 2021;23:1971-1978.
    PubMed         Abstract available

  16. CAIFFA T, De Luca A, Biagini E, Lupi L, et al
    Impact on clinical outcomes of right ventricular response to percutaneous correction of secondary mitral regurgitation.
    Eur J Heart Fail. 2021;23:1765-1774.
    PubMed         Abstract available

  17. STRACHINARU M, Nijveldt R, Vernooy K
    Arrhythmic risk management after acute myocarditis: never too early, only too late.
    Eur J Heart Fail. 2021;23:2055-2057.

  18. BARAN DA
    A deceptively simple problem: the case of cardiogenic shock.
    Eur J Heart Fail. 2021;23:1952-1954.

  19. CHIONCEL O, Metra M
    Cardiogenic shock centres for optimal care coordination and improving outcomes in cardiogenic shock.
    Eur J Heart Fail. 2021;23:1938-1941.

  20. PATTERSON T, Gregson J, Erglis A, Joseph J, et al
    Two-year outcomes from the MitrAl ValvE RepaIr Clinical (MAVERIC) trial: a novel percutaneous treatment of functional mitral regurgitation.
    Eur J Heart Fail. 2021;23:1775-1783.
    PubMed         Abstract available

  21. ENRIQUEZ-SARANO M, Benfari G, Messika-Zeitoun D, Grigioni F, et al
    Functional mitral regurgitation: a proportionate or disproportionate focus of attention?
    Eur J Heart Fail. 2021;23:1759-1762.

  22. USMAN MS, Pitt B, Butler J
    Target trial emulations: bridging the gap between clinical trial and real-world data.
    Eur J Heart Fail. 2021;23:1708-1711.

  23. CAMPOCHIARO C, De Luca G, Dagna L
    Cardiac immune-related adverse events: an immune-cardio-oncology puzzle.
    Eur J Heart Fail. 2021;23:1748-1749.

  24. GUAZZI M, Adamo M
    Cardiac output in severe tricuspid regurgitation: when more is less.
    Eur J Heart Fail. 2021;23:1795-1797.

  25. UNTERHUBER M, Kresoja KP, Besler C, Rommel KP, et al
    Cardiac output states in patients with severe functional tricuspid regurgitation: impact on treatment success and prognosis.
    Eur J Heart Fail. 2021;23:1784-1794.
    PubMed         Abstract available

  26. RIZZO S, De Gaspari M, Basso C
    Immune checkpoint inhibitor myocarditis: a call for standardized histopathologic criteria.
    Eur J Heart Fail. 2021;23:1736-1738.

  27. JACKSON AM, Petrie MC, Frogoudaki A, Laroche C, et al
    Hypertensive disorders in women with peripartum cardiomyopathy: insights from the ESC EORP PPCM Registry.
    Eur J Heart Fail. 2021;23:2058-2069.
    PubMed         Abstract available

  28. PALASKAS NL, Segura A, Lelenwa L, Siddiqui BA, et al
    Immune checkpoint inhibitor myocarditis: elucidating the spectrum of disease through endomyocardial biopsy.
    Eur J Heart Fail. 2021;23:1725-1735.
    PubMed         Abstract available

  29. LU DY, Adelsheimer A, Chan K, Yeo I, et al
    Impact of hospital transfer to hubs on outcomes of cardiogenic shock in the real world.
    Eur J Heart Fail. 2021;23:1927-1937.
    PubMed         Abstract available

  30. SUZUKI K, Claggett B, Minamisawa M, Packer M, et al
    Influence of study discontinuation during the run-in period on the estimated efficacy of sacubitril/valsartan in the PARAGON-HF trial.
    Eur J Heart Fail. 2021;23:2085-2090.
    PubMed         Abstract available

  31. SCHRAGE B, Beer BN, Savarese G, Dabboura S, et al
    Eligibility for mechanical circulatory support devices based on current and past randomised cardiogenic shock trials.
    Eur J Heart Fail. 2021;23:1942-1951.
    PubMed         Abstract available

  32. RUBIO-INFANTE N, Ramirez-Flores YA, Castillo EC, Lozano O, et al
    Cardiotoxicity associated with immune checkpoint inhibitor therapy: a meta-analysis.
    Eur J Heart Fail. 2021;23:1739-1747.
    PubMed         Abstract available

  33. GENTILE P, Merlo M, Peretto G, Ammirati E, et al
    Post-discharge arrhythmic risk stratification of patients with acute myocarditis and life-threatening ventricular tachyarrhythmias.
    Eur J Heart Fail. 2021;23:2045-2054.
    PubMed         Abstract available

  34. TREVISAN M, Fu EL, Xu Y, Savarese G, et al
    Stopping mineralocorticoid receptor antagonists after hyperkalaemia: trial emulation in data from routine care.
    Eur J Heart Fail. 2021;23:1698-1707.
    PubMed         Abstract available

  35. ZENG DX, Jiang JH
    Letter regarding the article 'Natural history and prognostic significance of iron deficiency and anaemia in ambulatory patients with chronic heart failure'.
    Eur J Heart Fail. 2021;23:1800.

  36. HALLIDAY BP, de Marvao A, Thilaganathan B
    Peripartum cardiomyopathy and pre-eclampsia: two tips of the same iceberg.
    Eur J Heart Fail. 2021;23:2070-2072.

  37. BEN GAL T, Ben Avraham B, Milicic D, Crespo-Leiro MG, et al
    Guidance on the management of left ventricular assist device (LVAD) supported patients for the non-LVAD specialist healthcare provider: executive summary.
    Eur J Heart Fail. 2021;23:1597-1609.
    PubMed         Abstract available

  38. PACKER M, Zannad F, Butler J, Filippatos G, et al
    Influence of endpoint definitions on the effect of empagliflozin on major renal outcomes in the EMPEROR-Preserved trial.
    Eur J Heart Fail. 2021;23:1798-1799.

    Selexipag and the Pulmonary Hypertension Continuum.
    Eur J Heart Fail. 2021 Nov 23. doi: 10.1002/ejhf.2387.

  40. TOMASONI D, Adamo M, Metra M
    November 2021 at a glance: focus on prevention, comorbidities, cardiogenic shock and novel devices.
    Eur J Heart Fail. 2021;23:1803-1805.

  41. FACILE A, Mewton N, Nguon M, Durand de Gevigney G, et al
    Primary endpoint adjudication: comparison between the expert committee and the regulatory MedDRA(R) coding in the MITRA-FR study.
    Eur J Heart Fail. 2022;24:396-398.

  42. TOMASONI D, Adamo M, Metra M
    December 2021 at a glance: focus on medical treatment, valvular heart disease and prognostic models.
    Eur J Heart Fail. 2021;23:1993-1994.

  43. WARRAICH HJ, Nohria A
    Is worsening renal function relevant without clinical context?
    Eur J Heart Fail. 2022;24:375-377.

  44. TREVISAN M, Fu EL, Carrero JJ
    Reply to the letter regarding the article 'Stopping mineralocorticoid receptor antagonists after hyperkalaemia: trial emulation in data from routine care'.
    Eur J Heart Fail. 2022;24:399-400.

  45. NIJHOLT KT, Westenbrink BD
    Reply to letter to the editor regarding the article 'Exercise: a molecular tool to boost muscle growth and mitochondrial performance in heart failure?'
    Eur J Heart Fail. 2022 Mar 26. doi: 10.1002/ejhf.2494.

  46. RASTOGI T, Ho FK, Rossignol P, Merkling T, et al
    Comparing and contrasting risk factors for Heart failure in patients with and without history of myocardial infarction: Data from HOMAGE and the UK Biobank.
    Eur J Heart Fail. 2022 Apr 1. doi: 10.1002/ejhf.2495.
    PubMed         Abstract available

  47. ALEXANDROU ME, Sarafidis PA
    Letter regarding the article 'Stopping mineralocorticoid receptor antagonists after hyperkalaemia: trial emulation in data from routine care'.
    Eur J Heart Fail. 2022;24:399.

  48. ROSENKRANZ S, Channick R, Chin KM, Jenner B, et al
    The impact of comorbidities on selexipag treatment effect in patients with pulmonary arterial hypertension: insights from the GRIPHON study.
    Eur J Heart Fail. 2022;24:205-214.
    PubMed         Abstract available

  49. COTTER G, Davison B, Metra M, Sliwa K, et al
    Amended STRONG-HF study design.
    Eur J Heart Fail. 2021;23:1981-1982.

    Reply to "Endomyocardial biopsy in the hands of the electrophysiologist: the 'one-stop shop' for arrhythmic non-ischaemic cardiomyopathy".
    Eur J Heart Fail. 2021;23:1984.

  51. VIDULA MK, Orlenko A, Zhao L, Salvador L, et al
    Plasma biomarkers associated with adverse outcomes in patients with calcific aortic stenosis.
    Eur J Heart Fail. 2021;23:2021-2032.
    PubMed         Abstract available

  52. WITTE KK, Goldberg SL, Kaye D, Starling R, et al
    Reply to 'Benefits of transvenous mitral annuloplasty in heart failure with lower degrees of functional mitral regurgitation'.
    Eur J Heart Fail. 2021;23:1985-1986.

  53. TOMASONI D, Adamo M, Metra M
    October 2021 at a glance: focus on imaging, biomarkers and comorbidities.
    Eur J Heart Fail. 2021;23:1569-1571.

  54. OBOKATA M, Reddy YNV, Melenovsky V, Sorimachi H, et al
    Uncoupling between intravascular and distending pressures leads to underestimation of circulatory congestion in obesity.
    Eur J Heart Fail. 2022;24:353-361.
    PubMed         Abstract available

  55. SINAGRA G, Porcari A, Fabris E, Merlo M, et al
    Standardizing the role of endomyocardial biopsy in current clinical practice worldwide.
    Eur J Heart Fail. 2021;23:1995-1998.

  56. VAN BERGEIJK KH, Voors AA, Wykrzykowska JJ
    Prime time for machine learning to predict clinical outcomes in valvular heart disease?
    Eur J Heart Fail. 2021;23:2033-2034.


  57. MORGAN H, Sinha A, Mcentegart M, Hardman SM, et al
    Evaluation of the causes of sex disparity in heart failure trials.
    Heart. 2022 Mar 31. pii: heartjnl-2021-320696. doi: 10.1136/heartjnl-2021-320696
    PubMed         Abstract available

    Int J Cardiol

  58. SU K, Li M, Wang L, Tian S, et al
    Clinical characteristics, predictors, and outcomes of heart failure with improved ejection fraction.
    Int J Cardiol. 2022 Mar 23. pii: S0167-5273(22)00405.
    PubMed         Abstract available

    J Mol Cell Cardiol

  59. ABDELLATIF M, Kroemer G
    Heart failure with preserved ejection fraction: An age-related condition.
    J Mol Cell Cardiol. 2022;167:83-84.

  60. GARBINCIUS JF, Luongo TS, Jadiya P, Hildebrand AN, et al
    Enhanced NCLX-dependent mitochondrial Ca(2+) efflux attenuates pathological remodeling in heart failure.
    J Mol Cell Cardiol. 2022;167:52-66.
    PubMed         Abstract available

    PLoS One

  61. HARRISON NE, Meram S, Li X, White MB, et al
    Hemodynamic profiles by non-invasive monitoring of cardiac index and vascular tone in acute heart failure patients in the emergency department: External validation and clinical outcomes.
    PLoS One. 2022;17:e0265895.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Chronic Heart Failure is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.